EyeGene Inc (KQ:185490) — Market Cap & Net Worth
Market Cap & Net Worth: EyeGene Inc (185490)
EyeGene Inc (KQ:185490) has a market capitalization of $45.69 Million (₩67.43 Billion) as of August 5, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #22186 globally and #1355 in its home market, demonstrating a 3.86% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying EyeGene Inc's stock price ₩1560.00 by its total outstanding shares 43222876 (43.22 Million). See 185490 capex to operating cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
EyeGene Inc Market Cap History: 2015 to 2026
EyeGene Inc's market capitalization history from 2015 to 2026. Data shows change from $328.89 Million to $45.69 Million (-15.92% CAGR).
Index Memberships
EyeGene Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$206.59 Billion | 0.02% | #640 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$206.59 Billion | 0.02% | #640 of 1384 |
Weight: EyeGene Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
EyeGene Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how EyeGene Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
EyeGene Inc's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $251.70 Million | $267.23 Million | -$8.27 Billion | 0.94x | N/A |
| 2017 | $436.29 Million | $301.03 Million | -$8.45 Billion | 1.45x | N/A |
| 2018 | $321.06 Million | $2.04 Billion | -$5.91 Billion | 0.16x | N/A |
| 2019 | $258.42 Million | $4.25 Billion | -$8.74 Billion | 0.06x | N/A |
| 2020 | $285.26 Million | $3.36 Billion | -$14.86 Billion | 0.08x | N/A |
| 2021 | $559.47 Million | $3.24 Billion | -$34.57 Billion | 0.17x | N/A |
| 2022 | $147.34 Million | $5.29 Billion | -$25.95 Billion | 0.03x | N/A |
| 2023 | $124.93 Million | $3.13 Billion | -$21.11 Billion | 0.04x | N/A |
| 2024 | $74.99 Million | $3.36 Billion | -$12.13 Billion | 0.02x | N/A |
| 2025 | $50.94 Million | $3.57 Billion | -$15.71 Billion | 0.01x | N/A |
Competitor Companies of 185490 by Market Capitalization
Companies near EyeGene Inc in the global market cap rankings as of August 5, 2026.
Key companies related to EyeGene Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
EyeGene Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, EyeGene Inc's market cap moved from $328.89 Million to $ 45.69 Million, with a yearly change of -15.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩45.69 Million | -10.29% |
| 2025 | ₩50.94 Million | -32.07% |
| 2024 | ₩74.99 Million | -39.98% |
| 2023 | ₩124.93 Million | -15.21% |
| 2022 | ₩147.34 Million | -73.66% |
| 2021 | ₩559.47 Million | +96.12% |
| 2020 | ₩285.26 Million | +10.39% |
| 2019 | ₩258.42 Million | -19.51% |
| 2018 | ₩321.06 Million | -26.41% |
| 2017 | ₩436.29 Million | +73.33% |
| 2016 | ₩251.70 Million | -23.47% |
| 2015 | ₩328.89 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of EyeGene Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $45.69 Million USD |
| MoneyControl | $45.69 Million USD |
| MarketWatch | $45.69 Million USD |
| marketcap.company | $45.69 Million USD |
| Reuters | $45.69 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About EyeGene Inc
EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which h… Read more